Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from...
Read moreDetails